Produktname:Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)- (9CI)

IUPAC Name:(1R,2S)-2-(4-fluorophenyl)cyclopropan-1-amine

CAS:220349-80-4
Molekulare Formel:C9H10FN
Reinheit:95%+
Katalognummer:CM433351
Molekulargewicht:151.18

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM433351-1g in stock ǵǵǵƄ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:220349-80-4
Molekulare Formel:C9H10FN
Schmelzpunkt:-
SMILES-Code:N[C@@H]1C[C@H]1C1=CC=C(F)C=C1
Dichte:
Katalognummer:CM433351
Molekulargewicht:151.18
Siedepunkt:
Mdl-Nr.:MFCD17010161
Lagerung:

Column Infos

Bomedemstat
Merck recently announces the initiation of the pivotal Phase 3 randomized MK-3543-006 clinical trial of Bomedemstat for Essential Thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) is critical for the regulation of hematopoietic stem and progenitor cells. Bomedemstat is an investigational small molecule irreversible inhibitor of LSD1 by suppressing progenitor cells during blood cell maturation. It is generally well tolerated in ET patients and demonstrates significant clinical activity as a monotherapy.
Bomedemstat has been granted Orphan Drug and Fast Track Designation for the treatment of ET and myelofibrosis (MF) by the U.S. FDA.